ClinicalTrials.gg
CompletedNCT00103610Updated Mar 13, 2014Results posted

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

A Phase 3 interventional study of Granulocyte colony-stimulating factor plus plerixafor and Granulocyte colony-stimulating factor plus placebo in Lymphoma, Non-Hodgkin, sponsored by Genzyme, a Sanofi Company. Completed at 32 sites in 2 countries. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Lymphoma, Non-Hodgkin.

Enrollment
Largest of 19
298 · median 36
Started
2005
with 3 others
Phase 3
2 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
8 of 19
Genzyme, a Sanofi Company

Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, this one has the largest enrollment, is one of 4 that started in 2005, is one of 2 in phase 3, and was the 2nd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in non-Hodgkin's lymphoma patients for autologous transplantation.

Read the detailed description

A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Currently filgrastim (G-CSF), a colony stimulating factor, is used to cause the growth and mobilization of stem cells from bone marrow to peripheral blood, which can then be collected from the peripheral blood by a process called apheresis. Plerixafor aids in the release of the stem cells from the bone marrow into the peripheral blood, possibly allowing for a more rapid collection of a larger number of stem cells from the peripheral blood. Larger stem cell doses for transplantation correlate to faster recovery times after high dose chemotherapy followed with stem cell transplantation. This study is intended to determine whether the combination of plerixafor with filgrastim is better than filgrastim alone in helping non-Hodgkin's lymphoma patients collect at least 5 million stem cells in four or less apheresis sessions.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Non-Hodgkin's lymphoma
  • Stem cell mobilization
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-Hodgkin's lymphoma in first or second complete or partial remission
  • (ECOG) performance status of 0 or 1
  • White Blood Cell count (WBC) > 2.5*10\^9/L
  • (PLT) > 100*10\^9/L

Exclusion criteria

Exclusion Criteria (Abbreviated List):

  • Failed previous stem cell collection
  • Prior or allogeneic transplant
  • or bone marrow involvement > 20%
  • Radiation to pelvis
  • Abnormal (ECG) with rhythm disturbance (ventricular arrhythmias) or other conduction abnormality
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
298 participants (actual)

Study arms

  • Experimental
    G-CSF plus plerixafor

    Drug: Granulocyte colony-stimulating factor plus plerixafor

  • Placebo comparator
    G-CSF plus placebo

    Drug: Granulocyte colony-stimulating factor plus placebo

Interventions

  • DrugGranulocyte colony-stimulating factor plus plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.

    Also known as: AMD3100, Mozobil

  • DrugGranulocyte colony-stimulating factor plus placebo

    Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis

    Proportion of participants achieving a target of ≥ 5\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.

    Time frame: Days 5 to 8

Secondary outcomes

  1. Number of Participants With Adverse Events

    Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.

    Time frame: up to Day 38

  2. Proportion of Participants Able to Achieve Target (>=2*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis

    Proportion of participants achieving a target of \>=2\*10\^6 CD34+ Cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.

    Time frame: up to Day 8

  3. Median Number of Days of Apheresis Required to Achieve >=5*10^6 CD34+ Cells/kg

    The Kaplan Meier estimate of median number of days (number of days at which 50% of participants reached the threshold, accounting for censored values) in each treatment arm to collect the target number of cells (≥5\*10\^6 CD34+ cells/kg) for transplantation. Central laboratory values were used.

    Time frame: up to Day 8

  4. Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment

    The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.

    Time frame: Up to Month 13

  5. Median Number of Days to Platelet (PLT) Engraftment

    The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\*10\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met.

    Time frame: Up to Month 13

  6. Graft Durability at 100 Days Post Transplantation

    The proportion of participants maintaining a durable graft at 100 days post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

    Time frame: approximately Day 138

  7. Graft Durability at 6 Months Post Transplantation

    The proportion of participants maintaining a durable graft at 6 months post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

    Time frame: approximately Month 7

  8. Graft Durability at 12 Months Post Transplantation

    The proportion of participants maintaining a durable graft 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

    Time frame: approximately Month 13

07

Results

Posted Sep 29, 2010

Participant flow

Participants with non-Hodgkin's lymphoma (NHL) eligible for autologous hematopoietic stem cell transplant were recruited from 31 centers in the U.S. and 1 in Canada. The first participant was randomized on 18 January 2005 and the last participant's last study visit occurred on 20 December 2007. A total of 298 participants were randomized.

Participant flow — Overall Study
MilestoneG-CSF Plus PlerixaforG-CSF Plus Placebo
Started150148
Completed11268
Not completed3880
Withdrew: Entered rescue procedure1052
Withdrew: Death1612
Withdrew: Elective withdrawal40
Withdrew: Lost to follow-up31
Withdrew: Adverse event22
Withdrew: Other27
Withdrew: Failed mobilization15
Withdrew: Noncompliance01

Outcome measures

PrimaryProportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis

Proportion of participants achieving a target of ≥ 5\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.

Time frame:
Days 5 to 8
Reported as:
Number · proportion of participants
Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion achieving target in ≤4 days0.5930.196
Proportion not achieving target in ≤4 days0.4070.804
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.

Time frame:
up to Day 38
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Adverse Events (AEs)146138
Related AEs9860
AEs Leading to early treatment termination33
AEs Leading to early study termination24
Grade 3 (severe) or 4 (life-threatening) AEs1114
SAEs810
SecondaryProportion of Participants Able to Achieve Target (>=2*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis

Proportion of participants achieving a target of \>=2\*10\^6 CD34+ Cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.

Time frame:
up to Day 8
Reported as:
Number · proportion of participants
Proportion of Participants Able to Achieve Target (>=2*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion achieving target in ≤4 days0.8670.473
Proportion not achieving target in ≤4 days0.1330.527
SecondaryMedian Number of Days of Apheresis Required to Achieve >=5*10^6 CD34+ Cells/kg

The Kaplan Meier estimate of median number of days (number of days at which 50% of participants reached the threshold, accounting for censored values) in each treatment arm to collect the target number of cells (≥5\*10\^6 CD34+ cells/kg) for transplantation. Central laboratory values were used.

Time frame:
up to Day 8
Reported as:
Median · Days
Median Number of Days of Apheresis Required to Achieve >=5*10^6 CD34+ Cells/kg
DaysG-CSF + PlerixaforG-CSF Plus Placebo
Median Number of Days of Apheresis Required to Achieve >=5*10^6 CD34+ Cells/kg3.0 (1.0 to NA)NA (NA to NA)
SecondaryMedian Number of Days to Polymorphonuclear (PMN) Cell Engraftment

The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.

Time frame:
Up to Month 13
Reported as:
Median · Days
Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment
DaysG-CSF Plus PlerixaforG-CSF Plus Placebo
Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment10.0 (10.0 to 11.0)10.0 (10.0 to 11.0)
SecondaryMedian Number of Days to Platelet (PLT) Engraftment

The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\*10\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met.

Time frame:
Up to Month 13
Reported as:
Median · Days
Median Number of Days to Platelet (PLT) Engraftment
DaysG-CSF Plus PlerixaforG-CSF Plus Placebo
Median Number of Days to Platelet (PLT) Engraftment20.0 (17.0 to 25.0)20.0 (18.0 to 25.0)
SecondaryGraft Durability at 100 Days Post Transplantation

The proportion of participants maintaining a durable graft at 100 days post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

Time frame:
approximately Day 138
Reported as:
Number · proportion of participants
Graft Durability at 100 Days Post Transplantation
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion of participants with durable graft0.9480.951
Proportion of participants without durable graft0.0520.049
SecondaryGraft Durability at 6 Months Post Transplantation

The proportion of participants maintaining a durable graft at 6 months post transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

Time frame:
approximately Month 7
Reported as:
Number · proportion of participants
Graft Durability at 6 Months Post Transplantation
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion of participants with a durable graft0.9760.987
Proportion of participants without a durable graft0.0240.013
SecondaryGraft Durability at 12 Months Post Transplantation

The proportion of participants maintaining a durable graft 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

Time frame:
approximately Month 13
Reported as:
Number · proportion of participants
Graft Durability at 12 Months Post Transplantation
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion of participants with a durable graft0.9821.0
Proportion of participants without a durable graft0.0180.0

Adverse events

Collected over Treatment emergent AEs covering Day 1 (start of G-CSF Mobilization to the day before starting chemotherapy (approximately Day 38).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G-CSF Plus Plerixafor—8/150 (5.3%)145/150 (96.7%)
G-CSF Plus Placebo—10/145 (6.9%)136/145 (93.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventG-CSF Plus PlerixaforG-CSF Plus Placebo
Atrial fibrillationCardiac disorders0/1502/145
Abdominal pain lowerGastrointestinal disorders0/1501/145
Non-cardiac chest painGeneral disorders0/1501/145
BacteraemiaInfections and infestations0/1501/145
Bacterial sepsisInfections and infestations0/1501/145
Pseudomonal sepsisInfections and infestations0/1501/145
SinusitisInfections and infestations0/1501/145
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1501/145
Renal failure acuteRenal and urinary disorders0/1501/145
Febrile neutropeniaBlood and lymphatic system disorders1/1500/145
Most frequent other events
Showing 10 of 241
Most frequent other events
EventG-CSF Plus PlerixaforG-CSF Plus Placebo
DiarrhoeaGastrointestinal disorders65/15020/145
NauseaGastrointestinal disorders50/15024/145
Injection site erythemaGeneral disorders48/15010/145
Bone painMusculoskeletal and connective tissue disorders40/15041/145
FatigueGeneral disorders40/15033/145
HeadacheNervous system disorders37/15027/145
Back painMusculoskeletal and connective tissue disorders31/15030/145
ParaesthesiaNervous system disorders27/15030/145
HypokalaemiaMetabolism and nutrition disorders25/15020/145
ArthralgiaMusculoskeletal and connective tissue disorders23/15019/145

Baseline characteristics

Age, Continuous
Age, Continuous(years)G-CSF Plus PlerixaforG-CSF Plus PlaceboTotal
Mean55.1 ± 10.957.5 ± 10.356.3 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)G-CSF Plus PlerixaforG-CSF Plus PlaceboTotal
Female504696
Male100102202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)G-CSF Plus PlerixaforG-CSF Plus PlaceboTotal
Caucasian136140276
African-American617
Asian224
Hispanic/Latino549
Other112
08

Study locations

32 sites
  • City of Hope Samaritan Bone Marrow Transplant Program
    Phoenix, Arizona 85006, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Shands Teaching Hospital, University of Florida
    Gainesville, Florida 32610, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana Blood and Marrow Transplantation Center
    Beech Grove, Indiana 46107, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Kansas City Cancer Center
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Nebraska Medical Center: Clarkson and University Hospitals
    Omaha, Nebraska 68198, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Wilford Hall Medical Center
    Lackland AFB, Texas 78236, United States
  • Texas Transplant Institute
    San Antonio, Texas 78229, United States
  • University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
09

References and documents

Publications

  • DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009 Oct 1;27(28):4767-73. doi: 10.1200/JCO.2008.20.7209. Epub 2009 Aug 31. PubMed 19720922 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Jul 2006 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2005
First posted
Feb 14, 2005
Start
Jan 2005
Primary completionActual
Jul 2006
CompletionActual
Dec 2007
Results first posted
Sep 29, 2010
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00103610
First posted
Feb 14, 2005
Start date
Jan 2005
Primary completion
Jul 2006
Completion
Dec 2007
Results posted
Sep 29, 2010
Last update
Mar 13, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion